<div id="readability-page-1">Money Markets Is It Time To Buy Intuitive Surgical Stock?  ByTrefis Team ,  Contributor.  Forbes contributors publish independent expert analyses and insights. Building a platform to do the job of 1 million analysts for  Great Speculations Follow Author Dec 05, 2025, 11:37am EST Share Save Comment  CHONGQING, CHINA - JULY 19: In this photo illustration, a person holds a smartphone displaying the logo of Intuitive Surgical Inc. (NASDAQ: ISRG), on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images) Getty Images Intuitive Surgical (ISRG) stock may represent a worthwhile investment at present. Why? Because you receive high margins – indicative of pricing power and cash generation capability – at a discounted price. Companies like this yield consistent, predictable profits and cash flows, which mitigate risk and enable capital reinvestment. The market often rewards this approach.  Intuitive Surgical is the global leader in robotic-assisted surgery, best known for its da Vinci surgical system, which helps hospitals and surgeons perform minimally invasive procedures with greater precision, efficiency, and safety—driving recurring revenue through instruments, services, and system upgrades.  What Is Happening With ISRG  ISRG has risen 8.9% thus far this year, yet it is actually 12% cheaper based on its P/S (Price-to-Sales) ratio in comparison to one year ago.  Here’s what is going well for the firm. Intuitive Surgical’s stock has increased by 8.9% year-to-date, demonstrating strong operational performance. Q3 2025 experienced a global increase in procedures by 20%, driven by significant adoption of the da Vinci 5 system, with 240 units installed, contributing to an installed base approaching 10,800 systems. This growing base, coupled with 85% recurring revenue from instruments and services, ensures robust cash generation. Management also raised full-year 2025 procedure growth projections to 17-17.5%, which indicates enduring strong demand and pricing power.  ISRG Has Strong Fundamentals  Recent Profitability: Almost 30.8% operating cash flow margin and 29.3% operating margin LTM.  Long-Term Profitability: Approximately 27.8% operating cash flow margin and 26.7% operating margin last 3-year average.  Revenue Growth: Intuitive Surgical witnessed a growth of 22.2% LTM and 16.3% last 3-year average, although this is not a growth story.  Available At Discount: At P/S multiple of 16.6, ISRG stock is offered at a 12% discount compared to one year ago.  Below is a brief comparison of ISRG fundamentals with S&amp;P medians.  MORE FOR YOU metrics Trefis *LTM: Last Twelve Months  Don’t Expect A Slam Dunk, Though  Although ISRG stock could be an attractive investment opportunity, it is always prudent to consider a stock’s previous drawdown history. ISRG fell by 82% in the Dot-Com crash and 76% during the Global Financial Crisis. The inflation shock led to a decline of nearly 50%, while the Covid sell-off resulted in a drop of around 40%. Even the correction in 2018 caused a 24% decline. The stock exhibits strong fundamentals, but these figures indicate it remains susceptible to adverse market conditions. However, the risk is not restricted solely to significant market crashes. Stocks can decline even during favorable market conditions – consider instances like earnings reports, business updates, or changes in outlook. Read ISRG Dip Buyer Analyses to learn how the stock has bounced back from sharp declines in the past.  If you seek further information, examine Buy or Sell ISRG Stock .  How We Arrived At ISRG Stock  ISRG caught our attention because it satisfied the following criteria:  Greater than $10 Bil in market cap  High CFO (cash flow from operations) margins or operating margins  Significantly declined in valuation over the past one year  But if ISRG doesn’t appear attractive to you, here are other stocks that also meet all these criteria:  Visa (V)  T-Mobile US (TMUS)  Salesforce (CRM)  Importantly, a portfolio established on 12/31/2016 with stocks that meet the criteria listed above would have performed as follows:  Average 12-month forward returns of nearly 19%  12-month win rate (percentage of selections returning positive) of approximately 72%  Portfolios Beat Stock Picking  Stocks can rise and fall – the secret is to remain invested. A balanced portfolio keeps you in the market, enhances gains, and mitigates single stock risk.  The Trefis High Quality (HQ) Portfolio , comprising 30 stocks, has a proven history of comfortably outperforming its benchmark that encompasses all three – the S&amp;P 500, S&amp;P mid-cap, and Russell 2000 indices. What accounts for this? As a category, HQ Portfolio stocks delivered superior returns with lower risk compared to the benchmark index; resulting in a smoother ride, as seen in HQ Portfolio performance metrics .  Editorial Standards Reprints &amp; Permissions LOADING VIDEO PLAYER... FORBES’ FEATURED Video</div>

直覺外科

<p>直覺外科 (ISRG) 的股票被認為是一項值得投資的選擇，因為它具有高利潤率、定價能力和現金生成能力。儘管其市銷率下降了 12%，但該股票年初至今上漲了 8.9%。作為機器人輔助手術的領導者，該公司在手術數量上增長了 20%，並且有着強勁的經常性收入。然而，歷史上的回撤表明其對市場條件的敏感性。包括 ISRG 在內的 Trefis 高質量投資組合表現優於基準，強調了平衡投資策略的重要性</p>